Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283385 | 0.93 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53MAPTMCHR1CYP1A2 | |
| SCHEMBL1615303 | 0.90 | MCHR1 (0.52) | SMN1; SMN2TP53MAPTMCHR1BRD4 | |
| SCHEMBL1283017 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2TP53MAPTCYP1A2CYP3A4 | |
| SCHEMBL1615069 | 0.85 | MAPT (0.50) | SMN1; SMN2TP53MAPTHTTPOLB | |
| SCHEMBL1614104 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53MAPTHTTNPSR1 | |
| SCHEMBL1615081 | 0.85 | TP53 (0.47) | SMN1; SMN2TP53MAPTMCHR1BRD4 | |
| SCHEMBL1282611 | 0.84 | DRD2 (0.48) | SMN1; SMN2MAPTMCHR1HPGD | |
| SCHEMBL1614727 | 0.84 | MAPT (0.54) | SMN1; SMN2TP53MAPTNPSR1POLB | |
| SCHEMBL14421341 | 0.84 | DRD2 (0.44) | SMN1; SMN2TP53MAPTMCHR1CYP1A2 | |
| SCHEMBL10282580 | 0.84 | MCHR1 (0.47) | TP53MAPTMCHR1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | SMN1; SMN2 3253/4885TP53 238/4885MAPT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.